In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

Hank, J A; Kohler, P C; Weil-Hillman, G; Rosenthal, N; Moore, K H; Storer, B; Minkoff, D; Bradshaw, J; Bechhofer, R; Sondel, P M

Hank, J A; Kohler, P C; Weil-Hillman, G; Rosenthal, N; Moore, K H; Storer, B; Minkoff, D; Bradshaw, J; Bechhofer, R; Sondel, P M.

Hank JA; Department of Human Oncology, University of Wisconsin, Madison 53792.

Cancer Res ; 48(7): 1965-71, 1988 Apr 01.

Article en En | MEDLINE | ID: mdl-3258180

Asunto(s)

Interleucina-2/uso terapéutico; Neoplasias/terapia; Células Cultivadas; Citotoxicidad Inmunológica; Inmunidad Innata; Inmunoterapia; Técnicas In Vitro; Activación de Linfocitos; Linfocitos/inmunología; Neoplasias/inmunología; Proteínas Recombinantes/administración & dosificación

Search on Google

Imprimir

XML

PubMed Links